Welcome to our dedicated page for VAR news (Ticker: VAR), a resource for investors and traders seeking the latest updates and insights on VAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VAR's position in the market.
On Nov. 17, 2022, Varian announced the initiation of the GENESIS II trial, the largest randomized clinical study of genicular artery embolization (GAE) aimed at treating mild to moderate knee osteoarthritis. Conducted at the Royal Berkshire NHS Foundation Trust in Reading, UK, the trial will evaluate the efficacy of Embozene microspheres in pain relief. With FDA Breakthrough Device Designation secured in October 2021, Embozene is marketed in 60 countries for embolization procedures. The trial includes a sham control group to ensure robust results and validate earlier findings from a smaller study.
Varian, in partnership with Cincinnati Children's/University of Cincinnati Medical Center, announced promising results from the FAST-01 clinical trial, the first human trial of ultra-high dose rate proton Flash therapy for bone metastases. Published in JAMA Oncology and presented at ASTRO 2022, the trial showed that 67% of treated sites experienced pain relief, with no significant toxicity reported. This innovative treatment, which delivers radiation in less than one second, indicates strong potential for future cancer care advancements, aiming to improve patient outcomes through more efficient precision therapy.
Varian, a Siemens Healthineers company, announced that Icon Group in Australia will be the first globally to implement the new ARIA oncology information system in early 2022. This system will streamline cancer care through enhanced clinical operations and multi-disciplinary functionality. Icon plans to deploy the ARIA system across its 44 global locations over several years. Additionally, Icon will introduce Varian's Noona electronic patient-reported outcomes solution to improve patient engagement and integrate real-time data into treatment practices.
Varian (NYSE: VAR) has partnered with Australia's Icon Group to enhance global cancer care by supplying 30 linear accelerators and related software. This collaboration aims to improve access to treatment in rural and underserved areas across Australia, Singapore, and China. The order includes Varian's advanced systems such as Halcyon™, TrueBeam®, and HyperArc™, which will be deployed in existing and new cancer centers. Varian's CEO expressed pride in collaborating with Icon Group to address the rising cancer burden and expand advanced care access globally.
Varian (NYSE: VAR) has partnered with Google Cloud to create an AI-driven diagnostic platform aimed at enhancing cancer treatment. Utilizing Google Cloud's Neural Architecture Search technology, the collaboration focuses on developing AI models for organ segmentation in radiation oncology, which is crucial for effective treatment planning. This initiative is expected to improve workflow efficiency and expand patient access to advanced therapies globally. Varian aims to integrate these AI models into its treatment planning tools, contributing to its mission of Intelligent Cancer Care™.
Varian (NYSE: VAR) announced an investment in Bend It Technologies, a company developing steerable microcatheters for minimally-invasive vascular procedures. These microcatheters offer 3D steerability, enhancing navigation through challenging anatomical structures. The Bendit technology has received FDA 510(k) clearance and CE Mark approval, facilitating safer and more efficient procedures. Varian's investment is part of Bend It's Series B funding, and a Varian representative will join Bend It's Board of Directors, potentially benefiting both companies as Varian expands its interventional medicine portfolio.
Varian (NYSE: VAR) announced CEO Dow Wilson will retire after 16 years, following the merger with Siemens Healthineers. Chris Toth, current President and COO, will succeed him. Wilson will assist as a special advisor during the transition. Under Wilson's leadership, Varian achieved double-digit growth, expanding its market leadership in cancer care and creating 4,000 jobs in five years. The transaction is expected to close in the first half of 2021.
Varian announced CEO Dow Wilson's retirement after 16 years, coinciding with its merger with Siemens Healthineers. Chris Toth, current President and COO, will succeed him as the CEO of Varian's segment within Siemens. Wilson will assist as a special advisor post-transition. Under Wilson's leadership since 2012, Varian achieved double-digit growth and expanded its market presence in cancer care, creating 4,000 jobs. The merger is anticipated to complete in H1 2021, furthering Varian's vision for innovative cancer treatment.
CTSI Oncology Solutions, a Varian company (NYSE: VAR), has signed a multi-year contract with CHRISTUS Health in Texas to offer technology-enabled services for radiation oncology across six clinics. The partnership aims to enhance operational efficiency, quality, and reduce costs through centralized support. Key components include the LION collaboration platform and a cloud-based version of Varian’s Eclipse treatment planning software. CHRISTUS will also implement six new linear accelerators, offering advanced tech and better patient care.
